思覺敏感
參考文獻

1 2  Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (1996). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia bulletin, 22(2), 283-303.
↑  Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML,
Tai JY, Shah MR, Foley CA, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68(4):546-557.
↑  Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2-3):131-142.
↑  Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America.Arch Gen Psychiatry. 2008;65(1):28-37.
↑  Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., ... & Borgwardt, S. (2012). Cognitive functioning in prodromal psychosis: a meta-analysis. Archives of general psychiatry, 69(6), 562-571.
↑  Lee, E. H., Ching, E. Y., Hui, C. L., Lin, J. X., Chang, W. C., Chan, S. K., & Chen, E. Y. (2017). Chinese label for people at risk for psychosis. Early Intervention in Psychiatry, 11: 224-228. doi:10.1111/eip.12232
↑  馬維芬, 楊芝菁, & 陳玉夏.(2013).嚴重精神疾病前驅期高危險群之篩檢預防議題分析. 護理雜誌, 60(3), 98-104.
↑  徐麗華，張天宏，＆王繼軍.(2015年).精神病風險綜合徵並非精神病前驅期。上海精神醫學，2015年01，42-44.
↑  Fusar-Poli, P., Yung, A. R., McGorry, P., & van Os, J. (2014). Lessons learned from the psychosis high-risk state: Towards a general staging model of prodromal intervention. Psychological Medicine, 44(1), 17-24. doi:http://dx.doi.org.eproxy.lib.hku.hk/10.1017/S0033291713000184
↑  Lee, E. H. M., Hui, C. L. M., Ching, E. Y. N., Lin, J., Chang, W. C., Chan, S. K. W., & Chen, E. Y. H. (2016). Public stigma in China associated with schizophrenia, depression, attenuated psychosis syndrome, and psychosis-like experiences. Psychiatric Services, 67(7), 766-770.
↑  Rüsch, N. W., Heekeren, K., Theodoridou, A., Dvorsky, D., Müller, M., Paust, T., . . . Walitza, S. (2013). Attitudes towards help-seeking and stigma among young people at risk for psychosis. Psychiatry Research, 210(3), 1313-1315.
↑  Fusar-Poli, P., Bonoldi, I., Yung, A. R., Borgwardt, S., Kempton, M. J., Valmaggia, L., ... & McGuire, P. (2012). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Archives of general psychiatry, 69(3), 220-229.
↑  Lam, M. M., Hung, S. F., & Chen, E. Y. (2006). Transition to psychosis: 6-month follow-up of a Chinese high-risk group in Hong Kong. Australian and New Zealand Journal of Psychiatry, 40:414-420.
↑  Thompson, A. R., Marwaha, S., & Broome, M. (2016). At-risk mental state for psychosis: Identification and current treatment approaches. BJ Psych Advances, 22(3), 186-193.
↑  McGorry PD., Nelson B., Markulev C., Yuen, H.P., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, IB., Berger, GE., Chen, E. Y., Haan, L., D., Nieman, DH., Nordentoft, M., Rössler, AR., Verma, S., Thompson, A., Yung, A., R., FRANZCP., Amminger, P., (2017). Effectofω-3 Polyunsaturated Fatty Acids inYoung People at Ultra high Risk for Psychotic Disorders. The NEURAPRO Randomized Clinical Trial. JAMA Psychiary, 74(1):19-27 doi:10.1001/jamapaychiatry.2016.29025
↑  Morrison, A. P., French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., ... & Bentall, R. P. (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk. The British Journal of Psychiatry, 185(4), 291-297.
↑  van der Gaag, M., Nieman, D. H., Rietdijk, J., Dragt, S., Ising, H. K., Klaassen, R. M., ... & Linszen, D. H. (2012). Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophrenia Bulletin, 38(6), 1180-1188.
↑  Puntis, Stephen; Minichino, Amedeo; De Crescenzo, Franco; Harrison, Rachael; Cipriani, Andrea; Lennox, Belinda. Cochrane Schizophrenia Group , 编. . Cochrane Database of Systematic Reviews. 2020-11-02, 2021 (2): CD013288. PMC 8092671 . PMID 33135811. doi:10.1002/14651858.CD013288.pub2 （英语）.